The relevance of congestion in the cardio-renal syndrome

Kidney International

Volumn 83, Issue 3, 2013, Pages 384-391

  Gnanaraj, Joseph F ^a   Von Haehling, Stephan ^b   Anker, Stefan D ^b,c   Raj, Dominic S ^d   Radhakrishnan, Jai ^e  

^a GRIFFIN HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

bioimpedance; endothelial activation; venous congestion; worsening renal function

Indexed keywords

ADENOSINE A1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; EPLERENONE; FERRIC CARBOXYMALTOSE; FUROSEMIDE; INTERLEUKIN 6; NESIRITIDE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RELAXIN; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL COMPARTMENT SYNDROME; ABDOMINAL PRESSURE; ACUTE HEART FAILURE; BIOIMPEDANCE; BREATHING DISORDER; CELL ACTIVATION; CENTRAL VENOUS PRESSURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPNEA; EXTRACORPOREAL ULTRAFILTRATION; HEART FAILURE; HORMONAL REGULATION; HUMAN; IMPEDANCE; IRON DEFICIENCY; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; LOW DRUG DOSE; ORTHOPNEA; PATIENT CARE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SINGLE DRUG DOSE; ULTRAFILTRATION; VASCULAR ENDOTHELIUM; VENOUS CONGESTION; WORSENING RENAL FUNCTION;

EID: 84874655235     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.406     Document Type: Review

References (73)

1. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-67
2. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110: 1514-1517
3. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210
4. Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for HF in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HF National Registry (ADHERE). Am Heart J 2005; 149: 209-216
5. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138: 285-290
6. Lynne WS. Design of therapy for advanced heart failure. Eur J Heart Fail 72005; 323-331
7. Labban B, Valeri A, Radhakrishnan J et al. The role of kidney biopsy in heart transplant candidates with kidney disease. Transplantation 2010; 89: 887-893
8. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure: Relationship of cardiac index to kidney function. Drugs 1990; 39(Suppl 4): 10-21
9. Ludwig C. Lehrhuch der Physiologie des Menschen 2, 2nd edn, Leipzig. 1861; 373
10. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol 1931; 72: 49-61
11. Damman K, Van Deursen VM, Navis G et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588
12. Drazner MH, Rame JE, Stevenson LW et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574-581
13. Guglin M, Rivero A, Garcia M et al. Renal dysfunction in HF is due to congestion and not due to low output. Clin Cardiol 2011; 34: 113-116
14. Testani JM, Khera AV, Kirkpatrick JN et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 105: 511-516
15. Mullens W, Abrahams Z, Tang WH et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-596
16. Nohria A, Hasselblad V, Stebbins A et al. Cardiorenal interactions: Insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268-1274
17. Sugrue M. Abdominal compartment syndrome. Curr Opin Crit Care 2005; 11: 333-338
18. Lambert DM, Marceau S, Forse RA. Intraabdominal pressure in the morbidly obese. Obes Surg 2005; 15: 1225-1232
19. Cheatham M, White MW, Sagraves SG et al. Abdominal perfusion pressure: A superior parameter in the assessment of intra-abdominal hypertension. J Trauma 2000; 49: 621-626
20. Mullens W, Abrahams Z, Skouri HN et al. Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal functioñJ Am Coll Cardiol 2008; 51: 300e6
21. Doty JM, Saggi BH, Sugerman HJ et al. Effect of increased renal venous pressure on renal function. J Trauma 1999; 47: 1000-1003
22. Kostreva DR, Seagard JL, Kampine JP et al. Reflex effects of renal afferents on the heart and kidney. Am J Physiol 1981; 241: R286-R292
23. Haddy FJ. Effect of elevation of intraluminal pressure on renal vascular resistance. Circ Res 1956; 4: 659-663
24. Dilley JR, Corradi A, Arendshorst WJ. Glomerular ultrafiltration dynamics during increased renal venous pressure. Am J Physiol 1983; 244: F650-F658
25. Prowle JR, Ishikawa K, Bellomo R. Renal plasma flow and glomerular filtration rate during acute kidney injury in man. Ren Fail 2010; 32: 349-355
26. Schrier RW. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8
27. Gottlieb SS, Brater DC, Thomas I et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-1353
28. Massie BM, O'Connor CM, Dittrich HC et al. PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 7 363: 1419-1428
29. Gimbrone MA Jr, Topper JN, Nagel T et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000; 902: 230-239
30. Ronco C, Haapio M, Bellomo R et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
31. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159
32. Sanchez-Lozada LG, Tapia E, Johnson RJ et al. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003; 64(Suppl. 86): S9-S14
33. von Haehling S, Jankowska EA, Anker SD et al. Anemia in heart failure: An overview of current concepts. Future Cardiol 2011; 7: 11
34. von Haehling S, Anker MS, Anker SD et al. Anemia in chronic heart failure: Can we treat? What to treat? HF Reviews 2012; 17: 203-210
35. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788
36. Sandek A, Von Haehling S, Anker SD et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-1569
37. Anker SD, Egerer KR, Coats AJ et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-1430
38. Attanasio P, Anker SD, Von Haehling S et al. Role of iron deficiency and anemia in cardio-renal syndromes. Semin Nephrol 2012; 32: 57-62
39. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided HF in adults? JAMA 1997; 277: 1712-1719
40. Maisel A, Mueller C, Anker SD et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839
41. Pfister R, Müller-Ehmsen J, Schneider CA et al. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Intern Med J 2011; 41: 467-472
42. Nyboer J. Impedance Plethysmography. Charles C Thomas: Springfield, MA, 1959
43. O'Brien C, Young AJ, Sawka MN. Bioelectrical impedance to estimate changes in hydration status. Int J Sports Med 2002; 23: 361-366
44. Parrinello G, Paterna S, Licata G et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. J Card Fail 2008; 14: 676-686
45. Saunders CE. The use of transthoracic electrical bioimpedance in assessing thoracic fluid status in emergency department patients. Am J Emerg Med 1988; 6: 337-340
46. Anand IS, Greenberg BH, Katra RP et al. Music Investigators. Design of the Multi-Sensor Monitoring in Congestive HF (MUSIC) study: Prospective trial to assess the utility of continuous wireless physiologic monitoring in heart failure. J Card Fail 2011 Jan 17: 11-16
47. Schoolwerth AC, Sica DA, Wilcox CS et al. Renal considerations in angiotensin converting enzyme inhibitortherapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-1991
48. Lassus J, Harjola VP, Nieminen MS et al. FINN-AKVA Study Group. Prognostic value of cystatin C in acute HF in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28: 1841-1847
49. Damman K, van Veldhuisen DJ, Hillege HL et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997-1000
50. Felker GM, Lee KL, O'Connor CM et al. NHLBI HF clinical research network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805
51. Salvador DR, Rey NR, Ramos GC et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, CD003178
52. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 1996; 17: 1867-1874
53. Knight EL, Glynn RJ, Avorn J et al. Predictors of decreased renal function in patients with HF during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138(5 Pt 1): 849-855
54. Gheorghiade M, Pang PS. Acute HF syndromes. Am Coll Cardiol 2009; 53: 557-573
55. Fagart J, Pook E, Kolkof P et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285: 1-9
56. Van Vliet AA, Donker AJ, Verheugt FW et al. Spironolactone in congestive HF refractory to high-dose loop diuretic and low-dose angiotensinconverting enzyme inhibitor. Am J Cardiol 1993; 71: 21A-28A
57. Hensen J, Abraham WT, Schrier RW et al Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention. Am J Nephrol 1991; 11: 441-446
58. Cheng JW. Nesiritide: Review of clinical pharmacology and role in HF management. Heart Dis 2002; 4: 199-203
59. O'Connor CM, Starling RC, Califf RM et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43
60. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491
61. Pan S, Chen HH, Simari RD et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA 2009; 106: 11282-11287
62. Goldberg LI. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 14: S21-S28
63. HF Network: ROSE Trial. Available at http://www.hfnetwork.org/hf-trials/ rose-trial. 64. Bart B, Boyle A, Kraemer M et al. Ultrafiltration versus usual care for hospitalized patients with heart failure RAPID CHF Trial. J Am Coll Cardiol 2005; 46: 2043-2046
64. Costanzo MR, Guglin ME, Teerlink JR et al. UNLOAD trial investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683
65. HF Network: CARRESS-HF Trial. Available at. https://www.hfnetwork.org/ hf-trials/carress-trial. 67. Sanchez JE, Rodriguez C, Pelaez B et al. [Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure]. Nefro-logia 2010; 30: 487-489
66. Khalifeh N, Vychytil A, Horl WH. The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney Int Suppl 2006; 103: S72-S75
67. Paterna S, Di Pasquale P, Parrinello G et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: A double blind study. J Am Coll Cardiol 2005; 45: 1997-2003
68. Ponikowski P, Metra M, Teerlink JR et al. Design of the RELAXin in acute HF study. Am Heart J 2012; 163: 149-155.e1
69. Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute HF (Pre-RE-LAX-AHF): A multicentre, randomised, placebo con rolled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439
70. Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cell Mol Life Sci 2006; 63: 1766-1779
71. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 2007; 297: 1319-1331
72. Anker SD, Comin Colet J, Ponikowski P et al. FAIR-HF trial investigators. Ferric carboxymaltose in patients with HF and iron deficiency. N Engl J Med 2009; 361: 2436-2448
73. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-ofprinciple cohort study. Lancet 2009; 373: 1275-1281